Charasteristics of the treatment of urinary disorders in postmenopausal women


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Overactive bladder syndrome (OAB) is very common. It has been shown that urge incontinence is more difficult for women than for men, sinse they have higher levels of stress, depression, and more pronounced sexual dysfunction. Material and methods. The study included 47 patients aged 54.6±3.5 years with symptoms of OAB. The Overactive Bladder Symptom Score (OABSS) was used to assess the symptoms, while the sexual function of the patients was evaluated using the Female Sexual Dysfunction Index (FSFI). In addition, Mini Mental State Examination (MMSE) scale was used for assessing the cognitive function. In comparison group there were 22 women who were comparable in socio-demographic characteristics, but didn’t have symptoms of OAB. The comparison between two groups was carried out using FSFI scale. Patients in the OAB group were prescribed trospium chloride (Spazmex®) 15 mg b.i.d. for three months, after which the patients completed the OABSS, FSFI, and MMSE questionnaires again. Results. All patients with OAB reported sexual dysfunction, which was significantly more profound than in the control group. The FSFI scores were, respectively, 15.23±6.12 versus 22.46±5.47. The average assessment of the cognitive abilities of patients with OAB was 27.9±1.4, which indicates that their cognitive functions were completely intact. The mean score on the OABSS scale was 11.8±2.7, and 11 women (23.4%) had a mild OAB, and 36 (76.6%) had moderate severity of symptoms. After three months of therapy, the mean score on the OABSS scale decreased by half, to an average of 5.4±1.2 points; the overall score of the FSFI approached the level of healthy women (20.64 and 22.46, respectively). The repeated assessment of the mental status did not reveal any changes, since the mean score of MMSE was 27.8±1.3. No significant adverse events were noted in any case. None of the patients required dose adjustment of the drugs that they received for concomitant diseases. Conclusion. All women with OAB syndrome had decreased sexual function compared to healthy women of the same age and social status. A three-month course of trospium chloride (Spazmex®), 30 mg daily, significantly improved both the parameters of urination and the sexual function, without having any adverse effect on their cognitive abilities. Moreover, there was no need to adjust the doses of drugs taken for concomitant diseases.

Full Text

Restricted Access

About the authors

E. V. Kulchavenya

TB Research Institute of Ministry of Health of Russia; Medical Center “Avicenna”; GBOU VPO Novosibirsk State Medical University of Ministry of Health of Russia

Email: urotub@yandex.ru
Ph.D., MD, professor, Chief Researcher at TB Research Institute of Ministry of Health of Russia; professor at Department of Tuberculosis of FGBOU VO Novosibirsk State Medical University of Ministry of Health of Russia, scientific Head of the Urologic Department of MC “Avicenna” Novosibirsk, Russia

L. S Treyvish

Medical Center “Avicenna”

Email: ms.lubov_tr@mail.ru
ead of the Gynecologic Department Novosibirsk, Russia

A. A. Baranchukova

TB Research Institute of Ministry of Health of Russia;GBOU VPO Novosibirsk State Medical University of Ministry of Health of Russia

Email: koshka.70@mail.ru
Ph.D., Head of the Department of Ultrasound Studies of TB Research Institute of Ministry of Health of Russia, associate professor of the Department of Tuberculosis of FGBOU VO Novosibirsk State Medical University of Ministry of Health of Russia Novosibirsk, Russia

References

  1. Abrams P., Cardozo L., Fall M, et al. The standardisation ofterminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
  2. Irwin D.E., Milsom I., Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-1314. discussion 1314-1305.
  3. Krivoborodov G.G., Tur E.I., SMrin D.A. Overactive bladder: disease concept and treatment approaches. Medical advice.2021;4:121-126. (Russian). @@ Кривобородов Г.Г., Тур Е.И., Ширин Д.А. Гиперактивный мочевой пузырь: концепция заболевания и подходы к лечению. Медицинский совет. 2021;4:121-126.
  4. Kazilov Yu.B., Gadzhieva Z.K. The prevalence of various urinary disorders. Urologiia. 2016;5:109-114.Russian @@Казилов Ю.Б., Гаджиева З.К. Распространенность различных нарушений мочеиспускания. Урология. 2016;5:109-114.
  5. Sarikaya S., Yildiz F.G., Senocak C., Bozkurt O.F., Karatas O.F. Urinary incontinence as a cause of depression and sexual dysfunction: Questionnaire-based study. Rev Int Androl. 2020; 18(2):50-54. Boi: 10.1016/j. androl.2018.08.003.
  6. Juliato C.R.T., Melotti I.G.R., Junior L.C.S., Britto L.G.O., Riccetto C.L.Z. Does the Severity of Overactive Bladder Symptoms Correlate With Risk for Female Sexual Dysfunction? J Sex Med. 2017;14(7):904-909. Doi: 10.1016/j. jsxm.2017.05.005.
  7. Zahariou A., Karamouti M, Tyligada E, et al. Sexual function in women with overactive bladder. Female Pelvic Med Reconstr Surg 2010;16:31-36.
  8. Homma Y., Yoshida M, Seki N., Yokoyama O, Kakizaki H., Gotoh M., Yamanishi T., Yamaguchi O., Takeda M., Nishizawa O. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology. 2006 Aug;68(2):318-323. doi: 10.1016/j.urology.2006.02.042.
  9. Wrobel A., Skorupska K., Rechberger E., Wozniak A., Miotla P., Kubik-Komar A., Skorupski P., Rechberger T. Reliability of the Polish version of the Overactive Bladder Symptom Score (OABSS) questionnaire: Correlation of the OABSS with urodynamic study and the UDI-6 and IIQ-7 questionnaires.Int Urogynecol J. 2019;30(12):2135-2139. doi: 10.1007/s00192-019-04060-2.
  10. Sawaqed F., Suoub M. Validating 7-items Overactive Bladder Symptom Score (OABSS) through Arabic linguistic version. Sci Rep. 2021;11(1):661. Boi: 10.1038/s41598-020-79974-9.
  11. Isidori A.M., Pozza C., Esposito K., et al. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med 2010;7 (03) 1139-1146. doi: 10.1111/j.1743-6109.2009.01635.x
  12. Folstein M.F., Folstein S.E., McHugh P.R. «Minimental state». A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189-198.
  13. Kulchavenya E.V., Zhukova I.I. Extrapulmonary tuberculosis - there are more questions than answers. Tuberculosis and lung disease. 2017;95(2):59-63.Russia @@Кульчавеня Е.В., Жукова И.И. Внелегочный туберкулез - вопросов больше, чем ответов. Туберкулез и болезни легких. 2017;95(2):59-63.
  14. Gadzhieva Z.K., Kazilov Yu.B., Alyaev Yu.G., Aboyan I.A., Kazilov B.R. Violation of urination. Do we all know about them? Urologiia. 2014;1:20-26.Russian @@Гаджиева З.К., Казилов Ю.Б., Аляев Ю.Г., Абоян И.А., Казилов Б.Р. Нарушения мочеиспускания. Все ли мы о них знаем? Урология. 2014;1:20-26.
  15. Kulchavenya E.V., Holtobin D.P. Overactive bladder in a difficult patient: which drug to choose? Urologiia. 2021;1:120-125.Russian @@Кульчавеня Е.В., Холтобин Д.П. Гиперактивный мочевой пузырь у сложного пациента: какой препарат выбрать? Урология. 2021;1:120-125.
  16. Lin X.D., Lin N., Ke Z.B., Xu N., Jiang P., Li H. Effects of overactive bladder syndrome on female sexual function. Medicine (Baltimore). 2021;100(20):e25761. doi: 10.1097/MD.0000000000025761.
  17. Neimark A.I.,Razdorskaya M.V., Gadzhieva Z.K. Estrogen deficiency and urinary incontinence in women in menopause. Urologiia. 2016;5:130-137.Russian @@Неймарк А.И., Раздорская М.В., Гаджиева З.К. Эстрогенодефицит и недержание мочи у женщин в климактерии. Урология. 2016;5:130-137.
  18. Kim Y.H., Seo J.T., Yoon H. The effect of overactive bladder syndrome on the sexual quality of life in Korean young and middle aged women.Int J Impot Res 2005;17:158-163.
  19. Gubbiotti M, Giannantoni A, Cantaluppi S, Coluccia A.C., Ghezzi F, Serati M. The impact of Mirabegron on sexual function in women with idiopathic overactive bladder. BMC Urol. 2019;19(1):7. doi: 10.1186/s12894-019-0438-8.
  20. Gomes T.A., Faber M.A., Botta B., Brito L.G.O., Juliato C.R.T. Severity of urinary incontinence is associated with prevalence of sexual dysfunction.Int Urogynecol J. 2020;31(8):1669-1674. doi: 10.1007/s00192-019-04092-8.
  21. Wang Y., Shi C, Wang Y., Jiao W., Wang X, Zhang J., Shi G., Wu D. The Correlation between Severity of Overactive Bladder Symptoms with Female Sexual Dysfunction and Sexual Satisfaction of Partners. Urol Int. 2021;105(1- 2):124-130. doi: 10.1159/000508764.
  22. Hajebrahimi S., Azaripour A., Sadeghi-Bazargani H. Tolterodine immediate release improves sexual function in women with overactive bladder. J Sex Med. 2008;5:2880-2885.
  23. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology 2004;64: 6 suppl 1:02-6.
  24. Illiano E., Mahfouz W, Giannitsas K., et al. Coital incontinence in women with urinary incontinence: an international study. J Sex Med 2018;15:1456-1462.
  25. Sand P.K., Goldberg R.P., Dmochowski R.R., et al. The impact ofthe overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006;195:1730-1735.
  26. Anastasiadis A.G., Davis A.R., Ghafar M.A, et al. The epidemiology and definition of female sexual disorders. World J Urol 2002;20:74-78.
  27. Raina R., Pahlajani G., Khan S., et al. Female sexual dysfunction: classification, pathophysiology, and management. Fertil Steril 2007;88:1273-1284.
  28. Salonia A., Munarriz R.M., Naspro R., et al. Women’s sexual dysfunction: a pathophysiological review. BJU Int 2004;93:1156-1164.
  29. Ergenoglu A.M., Yeniel A.O., Itil I.M., et al. Overactive bladder and its effects on sexual dysfunction among women. Acta Obstet Gynecol Scand 2013;92:1202-7.
  30. Cakir S.S., Degirmentepe R.B., Atalay H.A. The effect of overactive bladder treatment with anticholinergics on female sexual function in women: A prospective observational study.Int Urol Nephrol. 2019;51:27-32.
  31. Del Rosso A., Pace G., Di Pierro E.D. Impact of overactive bladder on sexual function in women. Urologia J. 2011;78:200-202.
  32. Balzarro M., Rubilotta E., Mancini V., Trabacchin N., Oppezzi L., Li Marzi V., Fusco F., Serati M. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis. Sex Med Rev. 2019;7(4):565-574. doi: 10.1016/j.sxmr.2019.05.002.
  33. Apolikhina I.A., Teterina T.A., Atamanova E.A. Differentiated approach to the treatment of overactive bladder in elderly and senile women. Obstetrics and gynecology.2020;9:234-240.Russian @@Аполихина И.А., Тетерина Т.А., Атаманова Е.А. Дифференцированный подход к терапии гиперактивного мочевого пузыря у женщин пожилого и старческого возраста. Акушерство и гинекология. 2020;9:234-240.
  34. Mota R.L. Female urinary incontinence and sexuality.Int Braz J Urol. 2017 Jan-Feb;43(1):20-28. doi: 10.1590/S1677-5538.IBJU.2016.0102.
  35. Kuzmin I.V., Al-Shukri S.Kh. Fesoterodine in the treatment of overactive bladder: pharmacological basis and clinical results. Urological statements. 2020;10(2):163-71.Russian @@Кузьмин И.В., Аль-Шукри С.Х. Фезотеродин в лечении гиперактивного мочевого пузыря: фармакологические основы и клинические результаты. Урологические ведомости.2020;10(2):163-71.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies